BioNTech’s BNT113 combo misses progression‑free survival endpoint in head‑and‑neck cancer trial

BioNTech announced that its investigational mRNA cancer therapy BNT113, given with pembrolizumab, failed to achieve a statistically significant improvement in progression‑free survival in the AHEAD‑MERIT Phase 2/3 study of HPV‑16‑positive head‑and‑neck cancer. The company said the trial will keep enrolling patients to evaluate overall survival, the second primary endpoint. The announcement was made on 13 Oct 2026 and the stock fell sharply in response.

The miss of the PFS endpoint removes a near‑term catalyst for the drug and has already pushed BioNTech’s share price down about 5% in pre‑market trading. The continuation of the trial means investors must wait for the OS read‑out before any potential upside can be reassessed.

  • 1The AHEAD‑MERIT Phase 2/3 trial did not meet its first dual primary endpoint of progression‑free survival for BNT113 plus pembrolizumab.
  • 2The Independent Data Monitoring Committee recommended that the study continue to assess overall survival, the second dual primary endpoint.
  • 3BioNTech received Fast Track designation from the U.S. FDA for BNT113 in January 2026.
  • 4BioNTech’s shares declined roughly 5% in pre‑market trading after the results were released.
  • 5The press release was issued on 13 Oct 2026.

Sources